News

April 23, 2019

Melanomas with NF-kB Activation Are Easier to Target with Immune Checkpoint Inhibitors, Study Says

News

Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about ... Read more

April 17, 2019

BioAtla and BeiGene Enter Collaboration to Develop BioAtla’s BA3071 Cancer Therapy

News

BioAtla and BeiGene entered into a collaboration agreement for the development, production, and commercialization of BioAtla’s BA3071, an investigational anti-CTLA-4 checkpoint blockade antibody. Checkpoint blockade therapies are based on ... Read more

April 16, 2019

VB10.NEO and NKTR-214 Work Together to Drive Complete, Durable Tumor Regression, Study Says

News

Vaccibody‘s VB10.NEO and Nektar Therapeutics‘ bempegaldesleukin (NKTR-214 or bempeg) work together to trigger a strong immune response against cancer cells, resulting in complete and durable tumor regression in a ... Read more

April 12, 2019

Early Phase 3 Trial Results of Tedopi for Advanced NSCLC Are Positive

News

Early results from the ATALANTE-1 Phase 3 trial indicate that Tedopi benefits people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior checkpoint inhibitor therapy, ... Read more

April 10, 2019

Trial Testing Triple Combo Immunotherapy in Newly-diagnosed Glioblastoma Completes Patient Enrollment

News

A Phase 1/2 clinical trial testing a triple immunotherapy combination for newly diagnosed glioblastoma has completed patient enrollment three months ahead of schedule. Inovio Pharmaceuticals, the company leading the ... Read more

April 9, 2019

OSE Immunotherapeutics, Léon Bérard Cancer Center to Collaborate Using AI

News

France’s OSE Immunotherapeutics and Léon Bérard Cancer Center have established a research collaboration to use analysis based on artificial intelligence (AI) to identify new targets for cancer immunotherapies. Under the ... Read more

April 5, 2019

Opdivo-Yervoy Combo Shrinks Aggressive Neuroendocrine Tumors, Phase 2 Trial Shows

News

A combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor size in four of 10 patients with aggressive neuroendocrine carcinoma, according to early results of a Phase 2 ... Read more

April 3, 2019

Phase 1 Study Begins Dosing High-Grade Glioma Patients with GMCI Combo Therapy

News

A Phase 1 study has started dosing patients who have newly diagnosed high-grade gliomas with a combination of Candel Therapeutics‘ gene-mediated cytotoxic immunotherapy (GMCI) plus Opdivo (nivolumab) and standard ... Read more

April 2, 2019

INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says

News

Therapy candidate INB03, meant to inactivate a kind immunosuppressive cell called myeloid-derived suppressor cells (MDSCs) while boosting anti-tumor immune cells, may help overcome resistance to immunotherapies, including immune checkpoint inhibitors, INmune ... Read more

March 29, 2019

Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows

News

Combining anti-PD-L1 immunotherapies with agents that inhibit the DNA damage response (DDR) significantly enhances anti-tumor immunity and leads to rapid tumor disappearance in mouse models of small cell lung cancer (SCLC), ... Read more

Pin It on Pinterest